Loading…
Merck (known as MSD outside US and Canada) announced a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, totaling approximately $11.5 billion equity value. Acceleron focuses on TGF-beta superfamily therapies, including sotatercept for pulmonary arterial hypertension and REBLOZYL for anemia.